Dr Reddys Laboratories is currently trading at Rs. 1662.65, up by 2.10 points or 0.13% from its previous closing of Rs. 1660.55 on the BSE.
The scrip opened at Rs. 1675.00 and has touched a high and low of Rs. 1675.00 and Rs. 1660.00 respectively. So far 2081 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1695.00 and Rs. 1626.00 respectively. The current market cap of the company is Rs. 28197.89 crore.
The promoters holding in the company stood at 25.61% while Institutions and Non-Institutions held 40.85% and 16.73% respectively.
Dr Reddys Laboratories has launched over the counter (OTC) Lansoprazole delayed release capsules in the US market following the company’s ANDA approval by United States Food & Drug Administration (USFDA).
The company will make the product under store brand lables in the US market. The product is the bioequivalent version of Novartis Consumer Health’s Prevacid 24 HR capsules which received Rx-to-OTC switch approval with 3 year exclusivity from the FGDA on March 18, 2009.
Recently, the company launched Clopidogrel Tablets, USP 75mg and 300mg, a bioequivalent generic version of Plavix in the US market. The ANDAs for Clopidogrel Tablets USP 75mg and 300mg are approved by the United States Food & Drug Administration (USFDA).
The company registered a growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total income increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.75 |
Dr. Reddys Lab | 1341.60 |
Cipla | 1476.45 |
Lupin | 2168.25 |
Zydus Lifesciences | 972.30 |
View more.. |